GRACEcast
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit cancerGRACE.org for more info.

Jennifer Brown, MD, discusses the choice in chemoimmunotherapy, FCR (fludarabine, cyclophosphamide and rituximab) vs BR. FCR has been the standard therapy for previously untreated fit patients with CLL under about the age of 70. While BR (bendamustine and rituximab), is a relatively newer therapy, which had been studied in a couple of phase two trials - smaller single arm trials and look to be promising.

Direct download: 01_Jennifer_Brown_04_FCR_v_BR-_Is_one_better-.mp4
Category:Blood-Cancers-Video -- posted at: 7:37pm PDT


Direct download: LC_VID_LIB_ASCO_2016_Rachel_Sanborn_Adj_chem_pt2.mp4
Category:Lung-Cancer-Video -- posted at: 8:03am PDT

Direct download: LCVL_ASCO_2016_-_Rachel_Sanborn_-_Adjuvant_Chem_pt.1.mp4
Category:Lung-Cancer-Video -- posted at: 11:44am PDT

GRACE is happy to present the 8th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016.

Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss new trials of targeting therapies used to treat leptomeningeal carcinomatosis.

Direct download: ASCO_2016_LC_RT_vid_9_New_Trials_of_Targeting_Therap.mp4
Category:Lung-Cancer-Video -- posted at: 11:00am PDT

GRACE is happy to present the 8th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016.

Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss promising early results for treatments targeting new mutations.


GRACE is happy to present the 6th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016.

Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss Immuno-oncology developments - combinations and use as first-Line therapy.

Direct download: LUNGSegment5-ImmunoDevelopments.mp4
Category:Lung-Cancer-Video -- posted at: 7:42pm PDT

GRACE is happy to present the 6th video in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016.  

Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss whether current evidence supports favoring proton beam radiation.

Direct download: Video_6_-_ASCO_2016_LC_RT_-_Does_Current_Evidence_Suppor.mp4
Category:Lung-Cancer-Video -- posted at: 1:50pm PDT

GRACE is happy to present the 5th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016.

Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss the J-Alex trial and whether Alecensa should replace Xalkori as First-Line ALK Therapy.

Direct download: Video_5_-_ASCO_2016_-LC_RT_-_J-Alex_Trial_Should_Alec.mp4
Category:Lung-Cancer-Video -- posted at: 1:30pm PDT

GRACE is happy to present the 9th video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer.  Featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016.

Drs. Weiss, Bauml and Seiwert discuss the topic of whether there are less toxic alternatives to the extreme regimen.


GRACE is happy to present the 8th video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer.  Featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016.

Drs. Weiss, Bauml and Seiwert discuss the promising early data for the oral inhibitor Buparlisib.


7th video in our series ASCO 2016 Head and Neck Roundtable, featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD. Dr. Weiss moderates the discussion regarding ASCO 2016 HN RT-Using Immunotherapy as First-Line Treatment and in Combinations.


6th video in our series ASCO 2016 Head and Neck Roundtable, featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD. Dr. Weiss moderates the discussion regarding keynote 55: Pembrolizumab for heavily pre-treated patients.  


 

GRACE is happy to present the 3rd video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer.  Featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016.

Drs. Weiss, Bauml and Seiwert discuss the using biomarkers in immunotherapy.

 

 

Direct download: ASCO_2016_HN_RT_-_Using_Biomarkers_in_Immunotherapy.mp4
Category:Head-Neck-Video -- posted at: 10:19pm PDT

GRACE is happy to present the 4th video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer.  Featuring Jared Weiss, MD, Joshua Baumi, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016.

Drs. Weiss, Baumi and Seiwert discuss the common side effects of PD-1 inhibitors.


GRACE is happy to present the 3rd video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer.  Featuring Jared Weiss, MD, Joshua Baumi, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016.

Drs. Weiss, Baumi and Seiwert discuss the data presented from Keynote 12 - Nivolumab and Pembrolizumab. 


GRACE is happy to present the 2nd video in our series, ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer.  Featuring Jared Weiss, MD, Joshua Baumi, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016.

    Drs. Weiss, Baumi and Seiwert discuss the subject of Checkmate 141 and its results.


GRACE is happy to present the 4th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016.

Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss the subject of local consolidation therapies for oligomatastases.


GRACE is happy to present the 1st video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer.  Featuring Jared Weiss, MD, Joshua Baumi, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016.

Drs. Weiss, Baumi and Seiwert discuss the subject of the immune system and PD-1 inhibitors. 

Direct download: The_Immune_System_and_PD-1_Inhibitors.mp4
Category:Head-Neck-Video -- posted at: 11:52am PDT

GRACE is happy to present our ASCO 2016 Lung Cancer Roundtable series, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing topics presented at ASCO 2016.

Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss the subject of urine or blood testing instead of lung biopsy, showing promise for finding EGFR mutations. 

 

 


GRACE is happy to present our ASCO 2016 Lung Cancer Roundtable series, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing topics presented at ASCO 2016.

Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss the subject of online patient groups and if they can help speed the development of new targeted therapies.  A subject quite important to online groups such as our own GRACE.

Direct download: Online_Pt_Grps_Spd__Thrpies_ASCO2016_LC_RT_correct_sponsor.mp4
Category:Lung-Cancer-Video -- posted at: 7:35pm PDT

1st Video in the GRACE ASCO 2016 Lung Cancer Roundtable series, featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD. 

Dr. West moderates this roundtable discussion highlighting studies presented at ASCO 2016.  For this video, Rova-T is presented as showing promise in Small Cell Lung Cancer. 


CLL, Chronic Lymphocytic Leukemia, What is the significance of IGHV mutations and how they are assessed.  Presented by Jennifer Brown, M.D., Ph.D., Director of the CLL Center and the Dana-Farber Cancer Institute.


Not Your Father's CLL

Faculty member Dr. John Pagel, and an in-person audience of patients and caregivers joined GRACE for 'Not Your Father's CLL', webcast LIVE from Seattle, WA on April 22, 2016.

Dr. Pagel, Chief of the Hematologic Malignancies program for the expanded treatment and research of blood based cancers such as leukemia, multiple myeloma and lymphoma at Swedish Cancer Institute, spoke about current treatment options and the future of care, and took questions from both the in-person and online audiences.  We invite you to watch the video.

Direct download: GRACEcast_-_Not_Your_Fathers_CLL_with_Dr._John_Pagel.mp4
Category:Blood-Cancers-Video -- posted at: 4:22pm PDT

Dr. Jack West, Swedish Cancer Institute, discusses current trials seeking to determine the efficacy of combining immunotherapy agents in lung cancer.

Direct download: GRACEcast-526_Lung_West_Immunotherapy_Combinations.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Dr. Jack West, Swedish Cancer Institute, raises the question of whether to use immune checkpoint inhibitors as first-line treatment of lung cancer, alone or in combination with chemotherapy.

Direct download: GRACEcast-525_Lung_West_Immunotherapy_First_Line_Treatment.mp4
Category:Lung-Cancer-Video -- posted at: 3:42pm PDT

Dr. Jed Gorden, Swedish Cancer Institute, reviews the lung cancer screening process, including low-dose CT scanning, smoking cessation, follow-up testing and counseling, and describes the potential benefits.


Dr. Jed Gorden, Swedish Cancer Institute, describes the differences between bronchoscopy and endobronchial ultrasound, highlighting the advantages of EBUS in diagnosis and staging.

Direct download: GRACEcast-523_GCVL_LU_Bronchoscopy_EBUS.mp4
Category:Lung-Cancer-Video -- posted at: 7:59pm PDT

Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.

Direct download: GRACEcast-522_Lung_West_Maintenance_Therapy_Advanced_NSCLC.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.


Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.


Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology.


Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology.

Direct download: GRACEcast-518_GCVL_LU_Histology_Specific_Regimens_Squamous.mp4
Category:Lung-Cancer-Video -- posted at: 7:29pm PDT

Dr. Jack West, Swedish Cancer Institute, addresses the issue of choosing a first-line chemotherapy regimen based on an adenocarcinoma histology.


Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.

Direct download: GRACEcast-516_GCVL_LU_Bevacizumab_Role_Stage_IV_NSCLC.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Dr. Jack West, Swedish Cancer Institute, identifies the platinum-based chemotherapy doublet as the backbone of first-line treatment for the majority of NSCLC patients.


Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.


Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between systemic and radiation therapy.


Dr. Ross Camidge, University of Colorado, describes the second generation ALK-inhibitors which provide good options for ALK-positive NSCLC patients who have developed acquired resistance to crizotinib.


Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.


Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and response to treatment.

Direct download: GRACEcast-510_GCVL_LU_ROS-1_Rearrangements_Defined.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Dr. Ross Camidge, University of Colorado, describes ALK rearrangements and the characteristics of patients who most often have them.

Direct download: GRACEcast-509_GCVL_LU_ALK_Rearrangements_What_Who.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Dr. Ross Camidge, University of Colorado, discusses the potential benefits as well as the disadvantages of multiplex mutation testing.


Dr. Heather Wakelee, Stanford University Medical Center, evaluates the lack of evidence for the use of targeted therapies after surgery, and describes ongoing trials attempting to resolve that issue.

Direct download: GRACEcast-507_GCVL_LU_Targeted_Therapy_Post-Resection.mp4
Category:Lung-Cancer-Video -- posted at: 7:42pm PDT

Dr. Heather Wakelee, Stanford University Medical Center, lists standard adjuvant chemotherapy regimens, comparing their administration and uses.

Direct download: GRACEcast-506_GCVL_LU_Standard_Adjuvant_Chemotherapy_Regimen.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Dr. Heather Wakelee, Stanford University Medical Center, discusses the purpose of adjuvant chemotherapy, and which patients benefit most from it.


Dr. Benjamin Levy, Mount Sinai Health Systems, compares zoledronic acid and denosumab, two agents used for treatment of bone metastases in lung cancer.


Dr. Benjamin Levy, Mount Sinai Health Systems, explains how the rate of progression of a patient's cancer may affect treatment choices.


Dr. Benjamin Levy, Mount Sinai Health Systems, discusses platinum-based chemotherapy as the standard of care for advanced NSCLC patients without targetable genetic mutations.

Direct download: GRACEcast-502_GCVL_LU_Platinum_Doublets_First_Line_Treatment.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Dr. Benjamin Levy, Mount Sinai Health Systems, lists the goals of treating advanced NSCLC and the methods used to achieve those goals.

Direct download: GRACEcast-501_GCVL_LU_Goals_Treating_Advanced_NSCLC.mp4
Category:Lung-Cancer-Video -- posted at: 7:16pm PDT

Dr. David Harpole, Duke University Medical Center, compares traditional open thoracotomy with video-assisted thorascopic surgery, highlighting the advantages of the newer approach.


Dr. David Harpole, Duke University Medical Center, defines the concept of mediastinal node sterilization and its use after neoadjuvant therapy.


Dr. David Harpole, Duke University Medical Center, describes the sleeve resection and how it can help selected patients with large tumors retain lung function.

Direct download: GRACEcast-498_GCVL_LU_Sleeve_Resection_Defined.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Dr. David Harpole, Duke University Medical Center, describes the mediastinoscopy and its use in lung cancer staging.

Direct download: GRACEcast-497_GCVL_LU_Mediastinoscopy_Defined.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Dr. David Harpole, Duke University Medical Center, details the methods thoracic surgeons use to assess a patient's fitness for surgery.


Dr. David Harpole, Duke University Medical Center, describes how he assists patients with the surgical decision-making process.


Dr. Nasser Hanna, Indiana University Health, addresses the issue of prophylactic cranial irradiation (PCI) in locally advanced NSCLC.

Direct download: GRACEcast-494_GCVL_LU_Role_PCI_Locally_Advanced_NSCLC.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Dr. Nasser Hanna, Indiana University Health, discusses the possible role of immunotherapy in locally advanced NSCLC.


Dr. Nasser Hanna, Indiana University Health, lists chemo regiments appropriate for use with radiation in locally advanced NSCLC.


Dr. Nasser Hanna, Indiana University Health, reviews efforts to utilize targeted therapies as consolidation after chemoradiation in locally advanced NSCLC.


Dr. Nasser Hanna, Indiana University Health, considers the use of induction or consolidation chemotherapy for unresectable stage III NSCLC.


Dr. Nasser Hanna, Indiana University Health, discusses the development of chemoradiation as a standard of care for unresectable stage III NSCLC.


Dr. Nasser Hanna, Indiana University Health, describes the factors which determine whether stage III NSCLC is resectable.

Direct download: GRACEcast-488_GCVL_LU_Defining_Stage_III_Unresectable_NSCLC.mp4
Category:Lung-Cancer-Video -- posted at: 3:49pm PDT

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, details the trends in lung cancer demographics and changes in histology by race and gender.


Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses smoking, asbestos, radon and other risk factors for lung cancer.

Direct download: GRACEcast-486_GCVL_LU_Lung_Cancer_Risk_Factors.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the demographics and epidemiology of lung cancer.

Direct download: GRACEcast-485_GCVL_LU_Lung_Cancer_Demographics_Epidemiology.mp4
Category:Lung-Cancer-Video -- posted at: 4:04pm PDT

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the genetic risk (or lack thereof) for lung cancer.

Direct download: GRACEcast-484_GCVL_LU_Significant_Genetic_Lung_Cancer_Risks.mp4
Category:Lung-Cancer-Video -- posted at: 6:25pm PDT

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, describes the types of situations in which local therapy is appropriate for treating limited acquired resistance.


Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, evaluates a variety of particular systemic treatment agents for possible use in elderly patients.


Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the use of single agent vs. doublet chemotherapy in elderly patients.


Dr. Gerard Silvestri, Medical University of South Carolina, describes the steps necessary to work up a lung cancer diagnosis, from initial scan to choice of treatment.

Direct download: GRACEcast-480_GCVL_LU_Lung_Cancer_Workup_Basics.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Dr. Gerard Silvestri, Medical University of South Carolina, defines pulmonary function testing, and describes how lung cancer surgeons use them.

Direct download: GRACEcast-479_GCVL_LU_Pulmonary_Function_Tests_Use_Defined.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Dr. Gerard Silvestri, Medical University of South Carolina, discusses the use of PET scans in lung cancer workup.

Direct download: GRACEcast-478_GCVL_LU_PET_Scan_Imaging_Lung_Cancer_Workup.mp4
Category:Lung-Cancer-Video -- posted at: 4:32pm PDT

Dr. Gerard Silvestri, Medical University of South Carolina, describes several procedures used to obtain biopsy tissue in order to diagnose lung cancer.

Direct download: GRACEcast-477_GCVL_LU_Diagnosis_Lung_Cancer_Biopsy.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Dr. Gerard Silvestri, Medical University of South Carolina, discusses the benefits and drawbacks of lung cancer screenings.


Dr. Gerard Silvestri, Medical University of South Carolina, describes some of the typical presenting symptoms of lung cancer.


Dr. Nathan Pennell, Cleveland Clinic, evaluates chemotherapy sensitivity assays, describing the difficulties inherent in predicting response to chemotherapy agents.


Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.

Direct download: GRACEcast-473_GCVL_LU_HER2_Mutation_Positive_NSCLC.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.


Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.


Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.


Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.


Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the benefits of giving two additional cycles of chemotherapy in combination with radiotherapy for stage III NSCLC.


Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.


Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer.


Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in stage IIIA lung cancer.


Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and surgery, and discusses trial evidence for each approach.

Direct download: GRACEcast-464_GCVL_LU_Overall_Management_Stage_IIIA_Disease.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Dr. Mark Socinski, University of Pittsburgh Medical Center, defines the three compartments in stage III (locally advanced) NSCLC, each of which must be treated.


Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states which of these types tend to be resectable.


Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines the V20 standard for lung radiation and outlines the advantages of limiting dose and field size in lung radiation therapy.


Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, provides trial evidence showing that patients may not benefit from high dose chest radiation therapy vs. standard dose therapy.


Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines oligometastatic lung cancer and describes the recent trend toward the use of stereotactic body radiation therapy to treat it.

Direct download: GRACEcast-459_GCVL_LU_SBRT_Oligometastatic_Lung_Cancer.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, describes the history and current use of stereotactic radiation therapy for inoperable lung lesions.


Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, describes the use of stereotactic radiosurgery and stereotactic radiation therapy.


Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC discusses the feasibility of molecular marker testing and targeted therapy in the adjuvant or post-operative setting.


Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, provides evidence for the use of stereotactic body radiation therapy as an alternative to surgery for operable early stage lung cancer.


Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC describes the use of serum tumor markers in various types of cancer, and the lack of a useful serum tumor marker in lung cancer.


Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC defines the concept of cancer histology and gives examples of several lung cancer subtypes.


Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center reviews early trial data of immunotherapy agents for treatment of small cell lung cancer (SCLC).

Direct download: GRACEcast-452_GCVL_LU_Immunotherapy_Small_Cell_Lung_Cancer.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center discusses standard chemotherapy options for treatment of both sensitive and refractory small cell lung cancer (SCLC).

Direct download: GRACEcast-451_GCVL_LU_Second_Line_Chemotherapy_Options_SCLC.mp4
Category:Lung-Cancer-Video -- posted at: 2:52pm PDT